Expert Interview
Discussing the potential of Arrivent Biopharma's firmonertinib monotherapy and the ongoing phase 3 FURVENT study for first-line EGFR exon20 insertion mutant non-small cell lung cancer (NSCLC)
Ticker(s): AVBP, JNJInstitution: University of Colorado
- Assistant Professor of Medicine in Oncology at University of Colorado.
- Treats over 20 patients with ALK-Positive lung cancer and leads multiple clinical trials investigating novel immunotherapy approaches for patients with lung cancer.
- Schenk Lab investigates the lung cancer tumor microenvironment as a contributor to lung cancer progression and treatment resistence.
How accurate do you think prevalence/incidence estiamtes are for EGFR exon20 ins mutant NSCLC?
Added By: wilson_adminDoes firmonertinib have the potential to supplant Rybrevant + chemo?
Added By: wilson_adminWhat is the likelihood of FURVENT to succeed?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
